Non-clinical safety of PTH-1A, inverse agonist, to support jansen metaphyseal chondrodysplasia (JMC) disease. POP: 09/16/2020 to 03/15/2020.
Ended Awarded Last action
- Contract number
- 75N95020F00001
- Awardee
-
IIT Research Institute UEI DGBUFQYMKWB5 Part of Illinois Institute Of Technology
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,053,804
Award facts
- Opportunity
-
- CRO Support for NCATS In Vitro and In Vivo Toxicology Studies Pre-Solicitation · N01TR17200217 · Posted Apr 7, 2020
- Contract value 100% obligated
- $3,053,804.06 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Chicago, IL 60616, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $50,726 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $35,459 | |
| Supplemental Agreement for work within scope | $20,875 | |
| Supplemental Agreement for work within scope | $59,000 | |
| Supplemental Agreement for work within scope | $201,709 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $698,273 | |
| Supplemental Agreement for work within scope | $1,304,478 | |
| Exercise an Option | $529,892 | |
| Original award | $153,392 |
Show all 11
About this award
This federal contract award was issued by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services. The $3,053,804.06 task order was awarded to the IIT Research Institute (IITRI), a non-profit division of the Illinois Institute of Technology, to provide non-clinical safety assessment of a drug candidate (PTH-1A, inverse agonist) to support the development of a treatment for Jansen Metaphyseal Chondrodysplasia disease. The work is being performed under NCATS' existing $48.6 million multiple-award contract for safety evaluation and toxicology studies. IITRI has extensive experience conducting preclinical drug development services for federal agencies across various therapeutic areas. The contract does not have a set-aside designation.
Quick answers
Who was awarded contract 75N95020F00001?
75N95020F00001 was awarded to IIT Research Institute by National Institute on Drug Abuse (National Institutes of Health) on September 16, 2020.
How much is contract 75N95020F00001 worth?
The government has obligated $3,053,804 on 75N95020F00001.
Which agency awarded contract 75N95020F00001?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95020F00001, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N95020F00001 an order under another contract?
Yes. 75N95020F00001 is a delivery order under HHSN271201700016I, an indefinite delivery contract, on CRO Support for NCATS In Vitro and In Vivo Toxicology Studies.
Was contract 75N95020F00001 competed?
The extent of competition for 75N95020F00001 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award